Home:
PCU3|2002: Col
David G McLeod, Sr, MD: Select Publications
Select publications
Boccardo F et al. Bicalutamide monotherapy versus flutamide
plus goserelin in prostate cancer patients: Results of an Italian
Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027-38.
Abstract
Iversen P et al. Casodex (bicalutamide) 150 mg monotherapy
compared with castration in patients with previously untreated nonmetastatic
prostate cancer: Results from two multicenter randomized trials
at a median follow-up of 4 years. Urology 1998;51(3):389-96.
Abstract
Marumo K et al. Erectile function and nocturnal penile
tumescence in patients with prostate cancer undergoing luteinizing
hormone-releasing hormone agonist therapy. Int J Urol 1999;6(1):19-23.
Abstract
Schellhammer PF. An evaluation of bicalutamide in the
treatment of prostate cancer. Expert Opin Pharmacother
2002;3(9):1313-28. Abstract
See WA et al. Bicalutamide as immediate therapy either
alone or as adjuvant to standard care of patients with localized
or locally advanced prostate cancer: First analysis of the early
prostate cancer program. J Urol 2002;168(2):429-35. Abstract
Tyrrell CJ et al. A randomised comparison of 'Casodex'
(bicalutamide) 150 mg monotherapy versus castration in the treatment
of metastatic and locally advanced prostate cancer. Eur
Urol 1998;33(5):447-56. Abstract
Wirth M et al. Bicalutamide (Casodex) 150 mg as immediate
therapy in patients with localized or locally advanced prostate
cancer significantly reduces the risk of disease progression.
Urology 2001;58(2):146-51. Abstract
|
